Literature DB >> 11400148

Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.

D Massi1, A Franchi, I Sardi, L Magnelli, M Paglierani, L Borgognoni, U Maria Reali, M Santucci.   

Abstract

Nitric oxide (NO) is synthesized by nitric oxide synthases (NOS) and plays an important role in tumour growth. In this study, inducible NOS (iNOS) expression was evaluated by immunohistochemistry in 34 melanocytic naevi (13 common melanocytic naevi, six Spitz naevi, and 15 so-called 'dysplastic naevi'), ten cutaneous melanomas in situ, 50 stage I invasive melanomas, and eight subcutaneous metastases of melanoma. In addition, four samples of melanocytic naevi and four samples of invasive melanomas were collected in order to perform western blot and northern blot analysis. By immunohistochemistry, melanocytic naevi never expressed iNOS. Among cases of melanoma in situ, two were negative, seven displayed staining in less than 20% of melanoma cells, and positivity was observed in 21-50% of melanoma cells in only one case. iNOS expression was detected in 46 out of 50 invasive melanomas (92%). Among these cases, 18 showed positivity in less than 20% of melanoma cells, 18 showed positivity in 21-50% of melanoma cells, and ten showed iNOS expression in more than 50% of cells. Statistical analysis revealed a significant difference in iNOS expression between melanocytic naevi and cutaneous melanomas (p<0.001). In addition, iNOS expression was significantly higher in invasive melanomas than in melanomas in situ (p=0.01). Among primary cutaneous melanomas, no significant correlation was found between iNOS expression and histopathological parameters (histotype, level, thickness and presence of regression/inflammatory infiltrate) and disease-specific survival. In subcutaneous melanoma metastases, iNOS expression was diffuse in more than 50% of cells. Statistical analysis revealed that subcutaneous melanoma metastases showed greater iNOS immunoreactivity than invasive melanomas (p=0.02). Molecular analyses confirmed that iNOS mRNA and protein were highly expressed in melanoma samples. In conclusion, iNOS was constantly absent in melanocytic naevi, whereas it was frequently expressed in melanomas, with up-regulation of the enzyme paralleling tumour progression. These data suggest that iNOS may play a role in the malignant transformation of melanocytes and in tumour growth. In addition, iNOS may be useful as an immunohistochemical marker for malignant melanocytic lesions. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11400148     DOI: 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  18 in total

1.  Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.

Authors:  Andrew G Sikora; Alexander Gelbard; Michael A Davies; Daisuke Sano; Suhendan Ekmekcioglu; John Kwon; Yared Hailemichael; Padmini Jayaraman; Jeffrey N Myers; Elizabeth A Grimm; Willem W Overwijk
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

2.  Stem cell factor affects tumour progression markers in metastatic melanoma cells.

Authors:  Francesca Prignano; Gianni Gerlini; Benedetta Salvatori; Claudio Orlando; Sandra Mazzoli; Nicola Pimpinelli; Silvia Moretti
Journal:  Clin Exp Metastasis       Date:  2006-09-22       Impact factor: 5.150

3.  Sphingosine 1-phosphate protects primary human keratinocytes from apoptosis via nitric oxide formation through the receptor subtype S1P₃.

Authors:  Elisabeth I Schmitz; Henrik Potteck; Melanie Schüppel; Marianti Manggau; Elly Wahydin; Burkhard Kleuser
Journal:  Mol Cell Biochem       Date:  2012-08-17       Impact factor: 3.396

4.  Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of γδ17 T cells in melanoma.

Authors:  Laetitia Douguet; Lloyd Bod; Renée Lengagne; Laura Labarthe; Masashi Kato; Marie-Françoise Avril; Armelle Prévost-Blondel
Journal:  Oncoimmunology       Date:  2016-08-10       Impact factor: 8.110

5.  β3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling.

Authors:  Massimo Dal Monte; Irene Fornaciari; Grazie Paola Nicchia; Maria Svelto; Giovanni Casini; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-06       Impact factor: 3.000

6.  Quantitative measurement of iNOS expression in melanoma, nasopharyngeal, colorectal, and breast tumors of Tunisian patients: comparative study and clinical significance.

Authors:  Emna Dabbeche-Bouricha; Nadia Hadiji-Abbes; Rania Abdelmaksoud-Damak; Nesrine Alaya; Wajdi Ayadi; Slim Charfi; Abdelmajid Khabir; Tahia Sellami-Boudawara; Raja Mokdad-Gargouri
Journal:  Tumour Biol       Date:  2015-11-07

7.  Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin.

Authors:  Luiz C Godoy; Chase T M Anderson; Rajdeep Chowdhury; Laura J Trudel; Gerald N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

Review 8.  Main roads to melanoma.

Authors:  Giuseppe Palmieri; Mariaelena Capone; Maria Libera Ascierto; Giusy Gentilcore; David F Stroncek; Milena Casula; Maria Cristina Sini; Marco Palla; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

9.  Molecular docking studies of quercetin and its analogues against human inducible nitric oxide synthase.

Authors:  Salam Pradeep Singh; Bolin Kumar Konwar
Journal:  Springerplus       Date:  2012-12-17

10.  Macrophage-tumor cell interactions regulate the function of nitric oxide.

Authors:  Michal A Rahat; Bernhard Hemmerlein
Journal:  Front Physiol       Date:  2013-06-18       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.